ClinicalTrials.gg
Enrolling by invitationNCT064371325-DUpdated Oct 1, 2026

Decoding Death and Dying in People With Dementia by Digital Thanotyping

An observational study in Dementia, sponsored by University of Bergen. Enrolling by invitation at 1 site in Norway. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by University of Bergen · Observational

How we know

Updated Oct 1, 2026Now Enrolling by invitationEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
270
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Dementia with a site in Norway — 12 open to participants now, 15 under way, 1 of them phase 3. Dementia · Norway.

Planned enrollment
11th of 19
270 · median 276
Started
2024
with 2 others
Observational
19 of 60
6 open now
Primary completion
2028-12
later than 11 of 14 live
Registered
50th of 60
by date
Lead sponsor
8 of 60
University of Bergen

Among the 60 studies in Dementia with a site in Norway, this one is the 11th largest by planned enrollment of the 19 observational ones that give a count, is one of 3 that started in 2024, is one of 19 observational ones, reaches primary completion later than 11 of the 14 other live ones, and was the 50th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

12 of the 60 studies in Dementia with a site in Norway are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Dementia with a site in Norway, or all of them as a file.
02

Study summary

How can healthcare professionals recognize that a person with dementia is at the end of life? When people are dying, their physical, mental, and social abilities are gradually declining. No reliable method of predicting perceived dying currently exists although the technology is available (sensors, algorithms).

The aim of Decoding Death and Dying in Dementia by Digital thanotyping (5-D) is to provide methods and tools to diagnose and describe dying to an unprecedented level of accuracy and robustness, within a timespan larger than is possible now, focusing on the case of dying people with dementia as one of the most vulnerable and difficult to study groups. 5-D combines clinical assessment tools with wearable sensing technology to monitor a) pain and distressing symptoms, b) behavioral and psychological symptoms in dementia (BPSD), c) oral changes, and to decode "the point of no return" as the beginning of perceived dying.

To obtain this outcome in nursing home patients with dementia, the investigator will test the main hypothesis: from monitoring the evolution of thanotype components over time and their interdependencies, the prediction of the "point of no return" is possible. The objectives of 5-D are:

O1. Collect data using sensors and validated assessment scales. O2. Develop estimation methods for BPSD from sensor measurements. O3. Develop digital tools to capture the expression of pain. O4. Determine the relationship between breathing and oral symptoms. O5. Develop models for symptom interdependencies at the end of life and the "point of no return".

O6. Perform human-in-the-loop validation of developed tools, models, and algorithms.

The ground-breaking interdisciplinary novelty of 5-D endeavors to enhance the understanding of end-of-life underlying pain and symptoms in people with dementia. Advancing our theoretical knowledge to uncover how, when, and why perceived dying can be identified opens the doors for transferable research across several scientific fields

Read the detailed description

Decoding death and dying in people with dementia by digital thanotyping (5-D) aims to pioneer the methodology of defining perceived dying by a data- and knowledge-driven digital representation of the end-of-life trajectory and its associated processes inferred from different measurements. The investigator proposes a novel digital thanotyping approach (Greek for thánatos) defined as the moment-by-moment in-situ quantification of the individual state of the human body. In 5-D, the investigator defines the "point of no return" as the declining state from which the person with dementia does not recover and marks the beginning of the perceived dying. In this trial the investigator describes methods and tools to define dying to an unprecedented level of accuracy and robustness, within a timespan larger than is possible now in one of the most difficult to access and vulnerable groups. Results will be transferable to other life-threatening diseases, relevant for hospitals and homecare services alike. The investigator hypothesizes that, from monitoring the evolution of clinical manifestations over time and their interdependencies, the prediction of the point of no return is possible.

5-D is a 5-year, multicenter, observation-analytic, longitudinal study aimed toward method development combining clinical data and information with systems modelling and systems identification. The investigator will recruit people with dementia (N=270) from the 14 Norwegian nursing homes (NH) from the Bergen Municipality, which have a cumulative capacity of >800 patients/year (out of a total of 2500 patients/year across the municipality). The recruitment pool will be extended, if necessary, to other NHs within the municipality. The investigator chooses NHs as the location for this research (instead of patient homes) because 57% of the dying population and 97% of all people with dementia in Norway die in NHs.(12) Most people in NHs present multimorbidity; among them, 52% have severe dementia (Mini-Mental-State Examination, MMSE score 0-11), 25% moderate dementia (MMSE 12-17), 16% mild dementia (18-23), and 6% no dementia (24-30).(13) Inclusion criteria: NH inhabitants >64 years, with significant cognitive impairment.(14) Exclusion criteria: people without informed/presumed consent, people already participating in other studies, people who might be distressed by sensors.

03

Conditions studied

  • Dementia

Browse trials for

Keywords

  • end of life
  • dementia
  • nursing home
  • pain assessment and treatment
  • symptom assessment and treatment
  • mouth care
  • agitation
  • sleep patterns
  • breathing
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

nursing home residents with dementia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Nursing home resident
  • >64 years old
  • People with dementia or who have a likely diagnosis of dementia
  • Score of \<4 on the 4 A's Test for Delirium (4AT) will be required for inclusion (no delirium)

Exclusion criteria

Exclusion Criteria:

  • People without dementia or cognitive impairment
  • People that are considered already in a health status emergency (\< 6 weeks to live)
  • People that are not living in the nursing home
  • People without informed/presumed consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
270 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Participants

    Persons with dementia

    Other: No intervention

Interventions

  • OtherNo intervention

    The study is observational and will not include any specific interventions other than the regular care practice that the participants receive from their care providers. The study will use a wrist-mounted smartwatch for monitoring (Garmin VivoActive5). Previous studies show acceptability toward wearable devices among persons with dementia. Moreover, the investigator will use Somnofy, VitalThings, a radar installation mounted behind the patients bed. Before starting the data collection, care staff will recognize any discomfort or distress potentially caused by the devices, in which case the relevant device will be immediately removed.

06

What researchers measure

Primary outcomes

  1. Edmonton Symptom Assessment System (ESAS++)

    Symptom assessment for palliative care period and the end of life period, with added items: death rattle, dyspnea, sleep disturbances, emesis specific to end of life. Likert scale 0-10; 0 indicating no symptoms and 10 is worst symptom.

    Time frame: Baseline and every 6.months (up to three years); When the patient is suggested to be at the end of life and is dying; ESAS will be assessed once the day.

  2. Digital biomarker estimations

    Digital biomarker estimations for behavioural and psychological disturbances (BPSD) e.g., apathy, agitation, pain, and sleep disturbances. Moreover, different types of breathing patterns (e.g., dyspnea, death rattle, lunge edema) Estimation of activity changes and selected BPSD resulting from the combined digital phenotype modeling; these estimations are experimental and "scores" will be based on analysis of found data after data collection period.

    Time frame: Baseline and every 6.months (up to three years), continuous up to 12 weeks if a serious health event occurs]

Secondary outcomes

  1. Activities of Daily Living (ADL) - Physical Self Maintenance Scale (PSMS), Lawton and Brody, 1969.

    Personal functional daily activities such as toileting, eating, self-care, movement/ambulation, transfers, bathing. 6 sections - scoring 1-5 on each, higher score indicates greater disability.

    Time frame: Baseline and every 6.months (up to three years)

  2. Neuropsychiatric Inventory - Nursing Home Version (NPI-NH)

    Validated in Norwegian nursing homes, measuring symptoms of behavioral and psychological symptoms of dementia (BPSD) such as: apathy, agitation, depression, anxiety, sleep disturbance, and appetite/eating. Gives scores 1-4 (higher numbers being daily occurance) for amount, 1-3 for intensity and burden of care related to symptom for caregiver (1-5) for each symptom.

    Time frame: Baseline and every 6.months (up to three years)

  3. Mobilization - Observation - Behavioral - Intensity - Dementia Pain Scale (MOBID-2)

    Measurement of pain specific to a dementia population; visual analog scale alongside likert scale 0-10, 0 being no pain and 10 being the worst pain, validated with persons with dementia

    Time frame: Baseline and every 6.months (up to three years)

  4. InterRai-Palliative Care (InterRai-PC)

    Oral health section only/specific of the InterRai-PC, assessment of symptoms

    Time frame: Baseline and every 6.months (up to three years)

  5. Oral inspection

    Biological material will be collected: 1. for gum and mucosal tissue status, unstimulated saliva will be collected 2. for carious lesions, collection of plaque samples will be collected from 2 teeth 3. oral dryness will be measured using an oral moisture-checking device 4. mucosal lesions diagnosis will be obtained from clinical pictures to determine deviation from normal healthy tissues.

    Time frame: Baseline and every 4.months (up to three years)

Other outcomes

  1. General Medical Health Rating Scale (GMHR)

    Mortality risk measure for general wellbeing, medical comorbidity, degree of somatic illness; top 2 scores are good, bottom 2 indicate serious illness with comorbidities. Bedside measure validated in NH with people with dementia.

    Time frame: Baseline

  2. Chart review

    A medication list will be compiled according to the Anatomical Therapeutic Chemical classification (ATC codes); including and of life, palliative treatment

    Time frame: Baseline

  3. Clinical Dementia Rating (CDR)

    Classification of cognitive impairment, 0 no cognitive impairment, 0.5 questionable impairment, 1 mild cognitive impairment, 2 moderate cognitive impairment, 3 severe cognitive impairment.

    Time frame: Baseline

  4. 4 A's Test for Delirium (4AT)

    Distinction between dementia and delirium for inclusion to study, \>4 indicates delirium; will be used as an exclusion criteria (participants must score \<4)

    Time frame: Baseline

  5. Clinical Frailty Scale (CFS)

    Mortality risk measure for general wellbeing, higher scores indicate greater disability (1-9)

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2028, 59 months after the start.

Of 272 non-industry observational studies under Dementia, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 202. This study's planned 59 months is below that.

Counting every sponsor, half of 294 studies reached it within 65 months; a quarter within 29 and three quarters within 188.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2024
First posted
May 31, 2024
StartActual
Jan 1, 2024
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Enrolling by invitation
changed Oct 1, 2026
Enrollment
480→270
Oct 1, 2026
Eligibility
Revised
Oct 1, 2026
Contact
No study contact listed any more: removed b•••@uib.no · •••4660; removed m•••@uib.no · •••8669
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Recruiting→Enrolling by invitation
    Enrollment 480→270
    Eligibility Revised
    Contact No study contact listed any more: removed b•••@uib.no · •••4660; removed m•••@uib.no · •••8669
    + 6 other changes: verification date, description, conditions, arm descriptions, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06437132
Collaborators
Leiden University, Harvard University, Yale University, Tohoku University, Bergen kommune
Responsible party
Bettina Husebo (Prof, MD, PhD, University of Bergen) — Principal investigator
First posted
May 31, 2024
Start date
Jan 1, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion